Tweets
GLP-1 Keeps on Working in PsA
Dr. David Liew | Abstract 2942 | ACR 2026
https://t.co/9lzyNq0RyS https://t.co/E7gjUj6Tgx
Dr. John Cush @RheumNow ( View Tweet )
3 hours 22 minutes ago
New FDA Approved for Polymyalgia Rheumatica - Secukinumab
The US Food and Drug Administration (FDA) approved secukinumab (Cosentyx) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate a https://t.co/kmgEiZIiFS
Dr. John Cush @RheumNow ( View Tweet )
4 hours 22 minutes ago
A Look Ahead: Precision, Safety and Access as Therapies Grow More Complex
ACR Convergence 2026 closed on a high note with the Clinical Year in Preview, a forward-looking session on the final day presented by Alexis Ogdie, MD, MSCE, of the University of Pennsylvania. https://t.co/br5LBqkqeu
Dr. John Cush @RheumNow ( View Tweet )
5 hours 22 minutes ago
Conducting a CAR-T Trial: A Pediatric Rheumatologist’s Reflections
At #ACR26, a scientific session titled “Program and Ethical Readiness in Pediatric Rheumatology: Building CAR Therapy Pathways for Rare Disease Care” addressed our readiness as a field for CAR-based therapies. https://t.co/qYWKJtTxmZ
Dr. John Cush @RheumNow ( View Tweet )
6 hours 53 minutes ago
One dose for every body? Rethinking drug exposure
Dr. Jiha Lee | Size Matters Session | ACR 2026
https://t.co/zodmhAZm1e https://t.co/kkBrQNmwXW
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Top 6 Practice-Changing Highlights from ACR26
The content at ACR Orlando was vast. We looked at several posters/listened to many talks, and heard from colleagues. So if we missed some great abstracts that will be practice-changing for you, we apologize in advance.
Here is our https://t.co/JmRpPh8Wzi
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Does a Gout Flare Increase Risk of a Cardiovascular Event?
In 2022, Cipolletta and colleagues published a JAMA study showing a temporal association between gout flares and subsequent major adverse cardiovascular events (MACE). This study reported 93% higher odds of MACE in the https://t.co/G91c9oz7tP
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Who benefits from GLP-1s in your rheumatology clinic?
Hear Dr. Catherine Bakewell tackle that question on Jan 30 at https://t.co/9THCAABeZ0. Kick off 2027 with rheumatology CME Jan 30–31 in Irving, TX, or live online.
Early-bird pricing through Dec 15. https://t.co/xjuAWKqAY9 https://t.co/9Nwx85xIb6
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Low PREVENT Score, Real Risk: Coronary Calcium and Heart Failure in Lupus
Dr. Akhil Sood | Abstracts 2861 0922 | ACR 2026
https://t.co/hREBmSbDQK https://t.co/wuiriT45zs
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Who gets left behind by the new SpA Criteria
Dr. Henrique Dalmolin & Dr. Carla Saad & Dr. Licia Mota | ACR 2026
https://t.co/SJhUVCZ8aZ https://t.co/vpe7ASo82Q
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
Biologics vs JAKi: MACE and VTE Risk in PsA
Dr. Sheila Reyes & Dr. Marina Magrey | Abstract 2304 | ACR 2026
https://t.co/IzafHHg9Me https://t.co/PGfQOk882R
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
JAKi CV Safety in Younger Adults
https://t.co/Cp7YEz0277 https://t.co/oBGRQjBuoH
Dr. John Cush @RheumNow ( View Tweet )
1 day ago
UPSTAND study: widespread pain responding to JAK inhibition
https://t.co/ZGouZSXaXU https://t.co/He2nXncsFF
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
Who might benefit from GLP-1s in your rheumatology clinic? Join Drs. Catherine Bakewell and Leonard Calabrese at https://t.co/9THCAABeZ0, Jan 30–31 in Dallas, TX, or live online. Kick off 2027 with 12.5 CME credits. Early bird pricing through Dec 15.
https://t.co/xjuAWKqAY9 https://t.co/xhqg94lmoy
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
Pioneers & Progress in Pediatric Rheumatology: The 50th Anniversary
Dr. Susan Shenoi | "Mastering the Field of Pediatric Rheumatology: Pioneers and Progress, 50th Anniversary" |ACR 2026
https://t.co/hSx8LHR99s https://t.co/cQNLQkT6qp
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
